Status:
COMPLETED
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Glomerulosclerosis, Focal Segmental
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
Eligibility Criteria
Inclusion
- Key
- APOL1 genotype of G1/G1, G2/G2, or G1/G2
- FSGS diagnosed by kidney biopsy
- Key
Exclusion
- Evidence of non-APOL1-mediated FSGS
- Participants with known sickle cell disease
- Solid organ or Bone marrow transplant
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
June 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 9 2021
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04340362
Start Date
June 8 2020
End Date
December 9 2021
Last Update
September 24 2025
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham - The Kirklin Clinic
Birmingham, Alabama, United States, 35294
2
California Institute of Renal Research
San Diego, California, United States, 92123
3
The George Washington University Medical Faculty Associates - Kidney Disease & Hypertension
Washington D.C., District of Columbia, United States, 20037
4
Howard University Hospital
Washington D.C., District of Columbia, United States, 20060